Yantai – September 09, 2026 -- CelluPro has become the first Chinese cell culture media supplier to receive EXCiPACTTM GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), a credential aimed at strengthening its position in global biomanufacturing supply chains.

Yantai – September 09, 2026 -- CelluPro has secured EXCiPACTTM GMP certification for pharmaceutical auxiliary materials, becoming the first China-based cell culture media supplier to achieve the credential.

Yantai, China – September 09, 2026 -- CelluPro has secured EXCiPACTTM GMP certification for pharmaceutical auxiliary materials, becoming the first Chinese cell culture media supplier to receive the internationally recognized credential.

Melbourne – – September 09, 2026 -- Nutromics, a Melbourne-based wearable diagnostics startup, has appointed Professor Kevin W. Plaxco, the inventor of its core DNA-based sensing technology, as Chief Scientific Officer ahead of its first product launch planned for 2027.

Seongnam, South Korea – September 09, 2026 -- Rznomics Inc. (KOSDAQ: 476830) has achieved up to a seven-fold increase in circular RNA (circRNA) production efficiency through engineering upgrades to its proprietary Self-Targeting and Splicing (STS) platform, according to peer-reviewed research published in Nucleic Acids Research on September 4, 2026.

Auckland – September 09, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that interim results from its MASTRR Registry found deep tissue infection in just 0.7% of patients treated with its Myriad Matrix and Myriad Morcells bioscaffolds, with no adverse events causally linked to the products.

Shanghai – September 09, 2026 -- Harbour BioMed (HKEX: 02142.HK) shares became eligible for trading under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, opening direct access for qualified mainland Chinese investors effective immediately.

Market capitalization crosses HK$10 billion threshold

The inclusion follows the Company's market capitalization steadily surpassing HK$10 billion, placing it among large- and mid-cap biopharmaceutical issuers on the Hong Kong exchange.

Shanghai – September 09, 2026 -- Clover Biopharmaceuticals (HKEX: 02197) reported positive preliminary Phase 2 data in Australia for two combination respiratory vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), targeting older adults aged 60-85.

Trial enrolled 420 older adults across multiple Australian sites

The randomized, observer-blinded study randomized 420 participants to receive SCB-1022, SCB-1033 or placebo. Antibody titers at 28 days post-vaccination were in line with or trended higher than prior Phase 1 results.

Yantai – September 09, 2026 -- CelluPro has become the first Chinese cell culture media supplier to receive EXCiPACTTM GMP Certification for Pharmaceutical Auxiliary Materials, adding an internationally recognized quality benchmark to its biomanufacturing supply chain.

Nottingham – September 09, 2026 -- Isomab Ltd has published a systematic review showing no increased cancer or retinopathy risk from pro-angiogenic therapies for coronary artery disease, removing a two-decade safety barrier that has constrained development across the field.